{"id":"NCT01934582","sponsor":"United Therapeutics","briefTitle":"A Pharmacokinetic Substudy of the TDE-PH-304 Protocol","officialTitle":"A Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15C SR (Treprostinil Diethanolamine) in the TDE-PH-304 Protocol","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2013-09-04","resultsPosted":"2016-10-27","lastUpdate":"2024-01-03"},"enrollment":13,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"UT-15C SR","otherNames":[]},{"type":"DRUG","name":"treprostinil diethanolamine","otherNames":["UT-15C Sustained Release (SR)"]}],"arms":[{"label":"Open label extension","type":"EXPERIMENTAL"}],"summary":"A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.","primaryOutcome":{"measure":"To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).","timeFrame":"Up to 14 days prior to transitioning to TID dosing regimen (PK Visit 1) and up to 35 days after transitioning to TID dosing regiment (PK Visit 2)","effectByArm":[{"arm":"PK Visit 1","deltaMin":8.12,"sd":null},{"arm":"PK Visit 2","deltaMin":6.75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Headache","Flushing","Nausea","Extremity pain","Diarrhea"]}}